ARTICLE | Politics, Policy & Law
Final reg reduces numbers of biopharma companies subject to CFIUS reviews
A final rule reduces the number of biopharma companies that will be subject to CFIUS reviews
January 18, 2020 4:12 AM UTC
Final regulations implementing the Foreign Investment Risk Review Modernization Act of 2018 released on Jan. 14 represent a partial victory for the biopharma industry, but the process is still certain to cast a cloud over foreign investment.
In FIRRMA, Congress expanded the jurisdiction of the Committee on Foreign Investment in the United States (CFIUS) to encompass non-controlling investments in U.S. businesses that could pose national security risks, but gave the Executive branch discretion to define those risks. ...